A 71-year-old man with Parkinson disease presents with tremor at rest and bradykinesia. Vital signs show BP 138/82 mmHg, HR 68 bpm, RR 16, temp 37.2°C. He is started on combination therapy to improve motor symptoms. The physician explains that one component increases levodopa bioavailability by inhibiting peripheral conversion to dopamine, preventing nausea and reducing required levodopa dosing. No orthostatic hypotension is noted. Which drug provides this peripheral decarboxylase inhibition?
- A)CarbidopaGABARITO
- B)Selegiline
- C)Amantadine
- D)Memantine
- E)Bromocriptine
Explicação
Carbidopa is the correct answer because it inhibits peripheral DOPA decarboxylase, does not cross the blood-brain barrier, and thereby increases CNS bioavailability of levodopa while reducing peripheral adverse effects such as nausea and hypotension. Ver explicação completa e trilha adaptativa →